Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
QLTI's Cash to Debt is ranked higher than
98% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. QLTI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
QLTI' s 10-Year Cash to Debt Range
Min: 0.7  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
QLTI's Interest Coverage is ranked higher than
97% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. QLTI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
QLTI' s 10-Year Interest Coverage Range
Min: 24.57  Med: 10000.00 Max: 9999.99
Current: No Debt
24.57
9999.99
F-Score: 4
Z-Score: 12.16
M-Score: -4.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -4.49
QLTI's ROE (%) is ranked higher than
69% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. QLTI: -4.49 )
Ranked among companies with meaningful ROE (%) only.
QLTI' s 10-Year ROE (%) Range
Min: -45.67  Med: -8.74 Max: 51.71
Current: -4.49
-45.67
51.71
ROA (%) -4.34
QLTI's ROA (%) is ranked higher than
70% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. QLTI: -4.34 )
Ranked among companies with meaningful ROA (%) only.
QLTI' s 10-Year ROA (%) Range
Min: -33.42  Med: -6.89 Max: 28.78
Current: -4.34
-33.42
28.78
ROC (Joel Greenblatt) (%) -217.90
QLTI's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. QLTI: -217.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
QLTI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -222.89  Med: -51.66 Max: 68.25
Current: -217.9
-222.89
68.25
EBITDA Growth (3Y)(%) -56.00
QLTI's EBITDA Growth (3Y)(%) is ranked lower than
94% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. QLTI: -56.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
QLTI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -56  Med: -3.90 Max: 85.3
Current: -56
-56
85.3
EPS Growth (3Y)(%) -47.70
QLTI's EPS Growth (3Y)(%) is ranked lower than
91% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. QLTI: -47.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
QLTI' s 10-Year EPS Growth (3Y)(%) Range
Min: -66.5  Med: -16.10 Max: 103.9
Current: -47.7
-66.5
103.9
» QLTI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

QLTI Guru Trades in Q3 2014

Jim Simons Sold Out
» More
Q4 2014

QLTI Guru Trades in Q4 2014

Jim Simons 218,687 sh (New)
First Eagle Investment 67,972 sh (New)
» More
Q1 2015

QLTI Guru Trades in Q1 2015

Jim Simons 341,324 sh (+56.08%)
First Eagle Investment 90,000 sh (+32.41%)
» More
Q2 2015

QLTI Guru Trades in Q2 2015

Charles Brandes 153,280 sh (New)
Jim Simons 564,415 sh (+65.36%)
First Eagle Investment Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with QLTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.25
QLTI's P/B is ranked higher than
89% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. QLTI: 1.25 )
Ranked among companies with meaningful P/B only.
QLTI' s 10-Year P/B Range
Min: 0.27  Med: 1.18 Max: 2.52
Current: 1.25
0.27
2.52
POCF 110.54
QLTI's POCF is ranked lower than
87% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 32.50 vs. QLTI: 110.54 )
Ranked among companies with meaningful POCF only.
QLTI' s 10-Year POCF Range
Min: 1.84  Med: 9.81 Max: 113.18
Current: 110.54
1.84
113.18
Shiller P/E 33.94
QLTI's Shiller P/E is ranked higher than
62% of the 112 Companies
in the Global Biotechnology industry.

( Industry Median: 44.71 vs. QLTI: 33.94 )
Ranked among companies with meaningful Shiller P/E only.
QLTI' s 10-Year Shiller P/E Range
Min: 33.73  Med: 80.93 Max: 524.5
Current: 33.94
33.73
524.5
Current Ratio 21.80
QLTI's Current Ratio is ranked higher than
92% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. QLTI: 21.80 )
Ranked among companies with meaningful Current Ratio only.
QLTI' s 10-Year Current Ratio Range
Min: 1.1  Med: 19.39 Max: 85.25
Current: 21.8
1.1
85.25
Quick Ratio 21.80
QLTI's Quick Ratio is ranked higher than
92% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. QLTI: 21.80 )
Ranked among companies with meaningful Quick Ratio only.
QLTI' s 10-Year Quick Ratio Range
Min: 1.07  Med: 19.17 Max: 85.25
Current: 21.8
1.07
85.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.34
QLTI's Price/Net Cash is ranked higher than
94% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. QLTI: 1.34 )
Ranked among companies with meaningful Price/Net Cash only.
QLTI' s 10-Year Price/Net Cash Range
Min: 1.07  Med: 4.37 Max: 87
Current: 1.34
1.07
87
Price/Net Current Asset Value 1.29
QLTI's Price/Net Current Asset Value is ranked higher than
94% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. QLTI: 1.29 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
QLTI' s 10-Year Price/Net Current Asset Value Range
Min: 0.48  Med: 3.34 Max: 44.53
Current: 1.29
0.48
44.53
Price/Tangible Book 1.27
QLTI's Price/Tangible Book is ranked higher than
91% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. QLTI: 1.27 )
Ranked among companies with meaningful Price/Tangible Book only.
QLTI' s 10-Year Price/Tangible Book Range
Min: 0.37  Med: 2.55 Max: 24.31
Current: 1.27
0.37
24.31
Price/Projected FCF 2.21
QLTI's Price/Projected FCF is ranked higher than
72% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. QLTI: 2.21 )
Ranked among companies with meaningful Price/Projected FCF only.
QLTI' s 10-Year Price/Projected FCF Range
Min: 0.28  Med: 1.68 Max: 250
Current: 2.21
0.28
250
Earnings Yield (Greenblatt) (%) -12.29
QLTI's Earnings Yield (Greenblatt) (%) is ranked lower than
61% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. QLTI: -12.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
QLTI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -12.29  Med: 9.70 Max: 409.1
Current: -12.29
-12.29
409.1

Analyst Estimate

Dec15 Dec16
EPS($) -0.66 -0.40
EPS without NRI($) -0.66 -0.40

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:QLT.Canada, QLT.Germany,
QLT Inc was formed in 1981 under the laws of the Province of British Columbia. It is a biotechnology company conducts development and commercialization of ocular products that address the unmet medical needs of patients and clinicians. The Company is developing QLT091001, a synthetic retinoid compound for the potential treatment of certain age-related and inherited retinal degenerative diseases. Its competitors include pharmaceutical and biopharmaceutical companies. The research and development, preclinical studies and clinical trials, and ultimately, the manufacturing, marketing and labelling of its products, are subject to extensive regulation by the FDA and other regulatory authorities in the U.S. and other countries.
» More Articles for QLTI

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: SWN, BECN, NSIT, HOLX, QLTI, THRX Aug 13 2012 
QLT Inc. Reports Operating Results (10-K) Mar 01 2011 
QLT Inc. (QLTI) CEO Robert Butchofsky buys 3,000 Shares Nov 08 2010 
QLT Inc. Reports Operating Results (10-Q) Nov 03 2010 
QLT Inc. (QLTI) CEO Robert Butchofsky buys 5,000 Shares Jun 23 2010 
QLT Inc. (QLTI) CFO Cameron Nelson buys 10,000 Shares Nov 10 2009 
QLT Inc. Reports Operating Results (10-Q) Nov 06 2009 
QLT Inc. (QLTI) CEO Robert Butchofsky buys 10,000 Shares Nov 04 2009 
QLT Inc. Reports Operating Results (10-Q) Aug 06 2009 
QLT Announces Second Quarter Results for 2009 Jul 28 2009 

More From Other Websites
QLT INC/BC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 04 2015
3:44 am QLT Inc provides update on its proposed acquisition of InSite Vision; reaffirms its support... Sep 04 2015
QLT Provides Further Update on Its Proposed Acquisition of InSite Vision Incorporated Sep 03 2015
QLT Provides Further Update on Its Proposed Acquisition of InSite Vision Incorporated Sep 03 2015
QLT INC/BC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Aug 28 2015
QLT and InSite Vision Agree on Amended and Restated Merger Agreement Aug 27 2015
InSite Vision and QLT Amend Merger Agreement Aug 27 2015
QLT INC/BC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 27 2015
QLT and InSite Vision Agree on Amended and Restated Merger Agreement Aug 27 2015
InSite Vision and QLT Amend Merger Agreement Aug 27 2015
InSite Vision Determines that an Unsolicited Offer from a Multi-National Pharmaceutical Company to... Aug 21 2015
QLT INC/BC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 21 2015
QLT Provides Update on Its Proposed Acquisition of InSite Vision Incorporated Aug 21 2015
QLT Provides Update on Its Proposed Acquisition of InSite Vision Incorporated Aug 21 2015
QLT INC/BC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 10 2015
QLT Provides Update on Merger With InSite Vision Incorporated Aug 10 2015
QLT Provides Update on Merger With InSite Vision Incorporated Aug 10 2015
QLT INC/BC Financials Aug 06 2015
QLT (QLTI) Reports Wider-than-Expected Loss in Q2 - Analyst Blog Jul 31 2015
QLT INC/BC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK